Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report

Jonathan B. Lamano, Jessica A. Quaggin-Smith, Craig Michael Horbinski, Matthew Christopher Tate, Sean A. Grimm, Priya U Kumthekar, Orin Bloch*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Survival outcomes for patients with glioblastoma (GBM)are universally poor with only a small percentage of patients surviving five years beyond initial diagnosis. Activation of the immune system against tumor cells is the basis of immunotherapy and aims to facilitate long-term immune surveillance and tumor suppression. Cytomegalovirus (CMV)has emerged as an immunologic target in GBM given that tumor cells have been shown to express the CMV-associated proteins IE1 and pp65. Moreover, vaccine therapy targeting CMV antigens has promoted improved survival outcomes with long-term survivors. In this report, we present the case of a 69 year-old woman with GBM who survived seven years post-diagnosis. Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses. Despite not receiving adjuvant temozolomide, the patient demonstrated a five year progression-free survival before requiring re-resection for radiation necrosis. Following re-resection, the patient survived for two additional years. As the patient's tumor stained positive for CMV antigens IE1 and pp65, it is hypothesized that she developed an immune response against CMV during recovery that contributed to anti-tumor surveillance and prolonged survival. Overall, this case supports further investigation into the role of CMV and immunotherapy in GBM.

Original languageEnglish (US)
Pages (from-to)18-21
Number of pages4
JournalJournal of Clinical Neuroscience
Volume64
DOIs
StatePublished - Jun 1 2019

Fingerprint

Colitis
Glioblastoma
Cytomegalovirus
temozolomide
Survival
Neoplasms
Immunotherapy
Abdominal Abscess
Antigens
Active Immunotherapy
Disease-Free Survival
Survivors
Immune System
Necrosis
Radiotherapy
Radiation

Keywords

  • Cytomegalovirus
  • Glioblastoma
  • IE1
  • Immunotherapy
  • pp65

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

@article{0010c3f133c14a419b49d61899de1bbf,
title = "Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report",
abstract = "Survival outcomes for patients with glioblastoma (GBM)are universally poor with only a small percentage of patients surviving five years beyond initial diagnosis. Activation of the immune system against tumor cells is the basis of immunotherapy and aims to facilitate long-term immune surveillance and tumor suppression. Cytomegalovirus (CMV)has emerged as an immunologic target in GBM given that tumor cells have been shown to express the CMV-associated proteins IE1 and pp65. Moreover, vaccine therapy targeting CMV antigens has promoted improved survival outcomes with long-term survivors. In this report, we present the case of a 69 year-old woman with GBM who survived seven years post-diagnosis. Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses. Despite not receiving adjuvant temozolomide, the patient demonstrated a five year progression-free survival before requiring re-resection for radiation necrosis. Following re-resection, the patient survived for two additional years. As the patient's tumor stained positive for CMV antigens IE1 and pp65, it is hypothesized that she developed an immune response against CMV during recovery that contributed to anti-tumor surveillance and prolonged survival. Overall, this case supports further investigation into the role of CMV and immunotherapy in GBM.",
keywords = "Cytomegalovirus, Glioblastoma, IE1, Immunotherapy, pp65",
author = "Lamano, {Jonathan B.} and Quaggin-Smith, {Jessica A.} and Horbinski, {Craig Michael} and Tate, {Matthew Christopher} and Grimm, {Sean A.} and Kumthekar, {Priya U} and Orin Bloch",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.jocn.2019.03.051",
language = "English (US)",
volume = "64",
pages = "18--21",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",

}

Long-term glioblastoma survival following recovery from cytomegalovirus colitis : A case report. / Lamano, Jonathan B.; Quaggin-Smith, Jessica A.; Horbinski, Craig Michael; Tate, Matthew Christopher; Grimm, Sean A.; Kumthekar, Priya U; Bloch, Orin.

In: Journal of Clinical Neuroscience, Vol. 64, 01.06.2019, p. 18-21.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term glioblastoma survival following recovery from cytomegalovirus colitis

T2 - A case report

AU - Lamano, Jonathan B.

AU - Quaggin-Smith, Jessica A.

AU - Horbinski, Craig Michael

AU - Tate, Matthew Christopher

AU - Grimm, Sean A.

AU - Kumthekar, Priya U

AU - Bloch, Orin

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Survival outcomes for patients with glioblastoma (GBM)are universally poor with only a small percentage of patients surviving five years beyond initial diagnosis. Activation of the immune system against tumor cells is the basis of immunotherapy and aims to facilitate long-term immune surveillance and tumor suppression. Cytomegalovirus (CMV)has emerged as an immunologic target in GBM given that tumor cells have been shown to express the CMV-associated proteins IE1 and pp65. Moreover, vaccine therapy targeting CMV antigens has promoted improved survival outcomes with long-term survivors. In this report, we present the case of a 69 year-old woman with GBM who survived seven years post-diagnosis. Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses. Despite not receiving adjuvant temozolomide, the patient demonstrated a five year progression-free survival before requiring re-resection for radiation necrosis. Following re-resection, the patient survived for two additional years. As the patient's tumor stained positive for CMV antigens IE1 and pp65, it is hypothesized that she developed an immune response against CMV during recovery that contributed to anti-tumor surveillance and prolonged survival. Overall, this case supports further investigation into the role of CMV and immunotherapy in GBM.

AB - Survival outcomes for patients with glioblastoma (GBM)are universally poor with only a small percentage of patients surviving five years beyond initial diagnosis. Activation of the immune system against tumor cells is the basis of immunotherapy and aims to facilitate long-term immune surveillance and tumor suppression. Cytomegalovirus (CMV)has emerged as an immunologic target in GBM given that tumor cells have been shown to express the CMV-associated proteins IE1 and pp65. Moreover, vaccine therapy targeting CMV antigens has promoted improved survival outcomes with long-term survivors. In this report, we present the case of a 69 year-old woman with GBM who survived seven years post-diagnosis. Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses. Despite not receiving adjuvant temozolomide, the patient demonstrated a five year progression-free survival before requiring re-resection for radiation necrosis. Following re-resection, the patient survived for two additional years. As the patient's tumor stained positive for CMV antigens IE1 and pp65, it is hypothesized that she developed an immune response against CMV during recovery that contributed to anti-tumor surveillance and prolonged survival. Overall, this case supports further investigation into the role of CMV and immunotherapy in GBM.

KW - Cytomegalovirus

KW - Glioblastoma

KW - IE1

KW - Immunotherapy

KW - pp65

UR - http://www.scopus.com/inward/record.url?scp=85063585489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063585489&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2019.03.051

DO - 10.1016/j.jocn.2019.03.051

M3 - Article

C2 - 30948314

AN - SCOPUS:85063585489

VL - 64

SP - 18

EP - 21

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

ER -